Medroxyprogesterone acetate - CAS 71-58-9
Catalog number: 71-58-9
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Progesterone Receptor
Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.
Publictions citing BOC Sciences Products
  • >> More
Baccatin III
1.[Medroxyprogesterone Acetate as Part of Palliative Care for Terminal-Stage Breast Cancer Patients-A Report of Two Cases].
Okamoto A1, Ueno H, Yamashiro A, Okada M, Nakasone A, Hatano T, Harada A, Taniguchi A, Onishi K, Kwon C, Fukazawa K, Taguchi T, Amaya F, Hosokawa T. Gan To Kagaku Ryoho. 2016 Mar;43(3):345-8.
Various effective strategies have recently been described in the treatment of breast cancer, including endocrine therapy, chemotherapy, and molecular-targeted therapy, providing long-term survival benefits even after cancer recurrence. However, terminal-stage patients experience side effects and worse quality of life(QOL), in addition to deterioration of their general condition caused by the progression of the disease itself. When providing the best supportive care, use of anti-cancer drugs is not taboo and can represent a good option as long as physical, social, psychological, and spiritual supports are provided to both the patients and their families. Medroxyprogesterone acetate(MPA)is an endocrine therapeutic drug. In Japan, MPA is used only as a late-line endocrine therapy for breast cancer recurrence because many other endocrine therapy drugs are much more effective and MPA increases the risk of thrombosis and obesity. Here, we report 2 patients with breast cancer who reached terminal stage more than 10 years after the first diagnosis.
2.Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma.
Sato M1, Arimoto T1, Kawana K1, Miyamoto Y1, Ikeda Y1, Tomio K1, Tanikawa M1, Sone K1, Mori-Uchino M1, Tsuruga T1, Nagasaka K1, Adachi K1, Matsumoto Y1, Oda K1, Osuga Y1, Fujii T1. Mol Clin Oncol. 2016 Apr;4(4):492-496. Epub 2016 Jan 28.
The aim of the present study was to evaluate whether measuring endometrial thickness during fertility-sparing treatment with medroxyprogesterone acetate (MPA) can be a predictive marker for effectiveness in women with endometrioid adenocarcinoma, grade 1 (EmCa, G1). A total of 32 patients with stage IA EmCa, G1 underwent treatment with MPA. Patients were <40 years of age and preferred fertility-sparing treatment. MPA (600 mg/day) with low-dose aspirin was administered orally for 26 weeks. Pathological evaluation was performed by total curettage at weeks 8 and 16 and by fractional curettage at week 26. Patients underwent curative surgery in case of disease progression. Endometrial thickness was measured by transvaginal ultrasonography at weeks 8 and 16. Patients who showed non-complete response (non-CR) had thicker endometrium than that of CR patients at weeks 8 and 16. Receiver operating characteristic analysis revealed cut-off values of 8.
3.Pharmaceutical treatments to prevent recurrence of endometriosis following surgery: a model-based economic evaluation.
Sanghera S1, Barton P2, Bhattacharya S3, Horne AW4, Roberts TE2; PRE-EMPT research group. BMJ Open. 2016 Apr 15;6(4):e010580. doi: 10.1136/bmjopen-2015-010580.
OBJECTIVE: Conduct an economic evaluation based on best currently available evidence comparing alternative treatments levonorgestrel-releasing intrauterine system, depot-medroxyprogesterone acetate, combined oral contraceptive pill (COCP) and 'no treatment' to prevent recurrence of endometriosis after conservative surgery in primary care, and to inform the design of a planned trial-based economic evaluation.
4.Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Lee O1, Choi MR1, Christov K2, Ivancic D1, Khan SA3. Cancer Lett. 2016 Apr 11. pii: S0304-3835(16)30241-5. doi: 10.1016/j.canlet.2016.04.010. [Epub ahead of print]
PURPOSE: Blockade of the progestogen-progesterone receptor (PR) axis is a novel but untested strategy for breast cancer prevention. We report preclinical data evaluating telapristone acetate (TPA), ulipristal acetate (UPA), and mifepristone.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Progesterone Receptor Products

(CAS: 209331-43-1)

CP-8668 is an orally active nonsteroidal progesterone receptor modulator with no significant affinity for human glucocorticoid receptor or human estrogen recept...

CAS 304853-42-7 Tanaproget

(CAS: 304853-42-7)

Tanaproget is a novel nonsteroidal progesterone receptor agonist that is first in its class and has high affinity and selectivity for the progesterone receptor....

CAS 126784-99-4 Ulipristal Acetate

Ulipristal Acetate
(CAS: 126784-99-4)

Ulipristal Acetate is an orally bioactive and selective progesterone receptor modulator (SPRM) used for emergency contraception and uterine fibroid. It binds to...

CAS 850-52-2 Altrenogest

(CAS: 850-52-2)

Altrenogest is a progestogen structurally related to veterinary steroid trenbolone.

CAS 71-58-9 Medroxyprogesterone acetate

Medroxyprogesterone acetate
(CAS: 71-58-9)

Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

CAS 152-62-5 Dydrogesterone

(CAS: 152-62-5)

Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.

CAS 57-83-0 Progesterone

(CAS: 57-83-0)

Progesterone, synthesized from cholesterol by the sequential action of desmolase in the mitochondria, plays an important role in brain function as a endogenous ...

(CAS: 240805-96-3)

JNJ-1250132, a new steroidal progestin antagonist, inhibits binding of the receptor to DNA in vitro. JNJ-1250132 induces a receptor conformation more similar to...

CAS 54024-22-5 Desogestrel

(CAS: 54024-22-5)

Desogestrel is a progestogen with low androgenic potency used in hormonal contraceptives..

CAS 297-76-7 Ethynodiol diacetate

Ethynodiol diacetate
(CAS: 297-76-7)

Ethynodiol diacetate is one of the first synthetic progestogens used in contraceptive pills.Relative to other 19-nortestosterone derivatives, it has relatively ...

CAS 60282-87-3 Gestodene

(CAS: 60282-87-3)

Gestodene is a progestogen hormonal contraceptive.Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the ...

CAS 7759-35-5 Nestoron

(CAS: 7759-35-5)

Nestorone is a steroidal progestin of the 19-norprogesterone group which is used as a hormonal contraceptive in several South American countries. It is a potent...

CAS 198414-30-1 Telapristone

(CAS: 198414-30-1)

Telapristone, the active metabolite of telapristone acetate (also known as CDB-4124), is a selective progesterone antagonist developed for the long-term treatme...

CAS 595-33-5 Megestrol Acetate

Megestrol Acetate
(CAS: 595-33-5)

Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HepG2.

CAS 65928-58-7 Dienogest

(CAS: 65928-58-7)

Dienogest(STS-557) is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis.

(CAS: 1262108-14-4)

Vilaprisan is a selective oral progesterone receptor antagonist under the development of Bayer HealthCare Pharmaceuticals. BAY 1002670 showed a marked dose-depe...

CAS 302-22-7 Chlormadinone acetate

Chlormadinone acetate
(CAS: 302-22-7)

Chlormadinone acetate, with antiandrogen and antiestrogenic activities it is a steroidal progestin used in combinations as an oral contraceptive.

CAS 199396-76-4 Asoprisnil

(CAS: 199396-76-4)

Asoprisnil is a selective progesterone receptor (PR) modulator developed for the treatment of progesterone sensitive myomata.

CAS 68-22-4 Norethindrone

(CAS: 68-22-4)

Norethindrone, a synthetic progestin, is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).

CAS 84371-65-3 Mifepristone

(CAS: 84371-65-3)

Mifepristone is a progesterone receptor antagonist(IC50= 0.2 nM) and a glucocorticoid receptor antagonist(IC50= 2.6 nM). It is used as an abortifacient in the f...

Chemical Structure

CAS 71-58-9 Medroxyprogesterone acetate

Quick Inquiry

Verification code

Featured Items